Verrica Pharmaceuticals Inc VRCA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 10:11 AM EDT
7.01quote price arrow up+0.09 (+1.37%)
Volume
5,927
52 week range
2.86 - 7.76
Loading...
  • Open6.84
  • Day High7.01
  • Day Low6.84
  • Prev Close6.92
  • 52 Week High7.76
  • 52 Week High Date07/21/23
  • 52 Week Low2.86
  • 52 Week Low Date11/14/23

Key Stats

  • Market Cap297.566M
  • Shares Out42.42M
  • 10 Day Average Volume0.21M
  • Dividend-
  • Dividend Yield-
  • Beta1.84
  • YTD % Change-5.4

KEY STATS

  • Open6.84
  • Day High7.01
  • Day Low6.84
  • Prev Close6.92
  • 52 Week High7.76
  • 52 Week High Date07/21/23
  • 52 Week Low2.86
  • 52 Week Low Date11/14/23
  • Market Cap297.566M
  • Shares Out42.42M
  • 10 Day Average Volume0.21M
  • Dividend-
  • Dividend Yield-
  • Beta1.84
  • YTD % Change-5.4

RATIOS/PROFITABILITY

  • EPS (TTM)-1.46
  • P/E (TTM)-4.80
  • Fwd P/E (NTM)-5.30
  • EBITDA (TTM)-62.668M
  • ROE (TTM)-224.08%
  • Revenue (TTM)5.124M
  • Gross Margin (TTM)85.44%
  • Net Margin (TTM)-1,307.47%
  • Debt To Equity (MRQ)224.03%

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Verrica Pharmaceuticals Inc

 

Profile

MORE
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In...
Paul Manning
Chairman of the Board
Ted White
President, Chief Executive Officer, Director
P. Terence Kohler Jr.
Chief Financial Officer
Christopher Hayes J.D.
General Counsel, Company Secretary, Chief Legal Office
Address
10 N High St Ste 200
West Chester, PA
19380-3014
United States

Top Peers

SYMBOLLASTCHG%CHG
XOMA
XOMA Corp
24.15-0.19-0.78%
PYXS
Pyxis Oncology Inc
4.74UNCHUNCH
VSTM
Verastem Inc
11.40+0.33+2.98%
HUMA
Humacyte Inc
2.98+0.11+3.83%
LYRA
Lyra Therapeutics Inc
5.31+0.04+0.80%